Department of Radiation Oncology, The Methodist Hospital, and The Methodist Hospital Research Institute, Houston, TX 77030, USA.
Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):79-84. doi: 10.1016/j.ijrobp.2009.07.1701. Epub 2009 Dec 11.
To perform a comprehensive literature review and analysis of cases dealing with choroid plexus carcinoma (CPC) to determine the optimal radiotherapy (RT) treatment field.
A PubMed search of English language articles from 1979 to 2008 was performed, yielding 33 articles with 56 patients who had available data regarding RT treatment field. The median age at diagnosis was 2.7 years (range, 1 month-53 years). Of 54 patients with data regarding type of surgery, 21 (38.9%) had complete resection. Chemotherapy was delivered to 27 (48%) as part of initial therapy. The RT treatment volume was the craniospinal axis in 38 (68%), whole brain in 9 (16%), and tumor/tumor bed in 9 (16%). Median follow-up for surviving patients was 40 months.
The 5-year overall survival and progression-free survival (PFS) rates were 59.5% and 37.2%, respectively. Complete resection (p = 0.035) and use of craniospinal irradiation (CSI; p = 0.025) were found to positively affect PFS. The 5-year PFS for patients who had CSI vs. whole brain and tumor/tumor bed RT were 44.2% and 15.3%. For the 19 patients who relapsed, 9 (47%) had a recurrence in the RT field, 6 (32%) had a recurrence outside the RT field, and 4 (21%) had a recurrence inside and outside the irradiated field.
Patients with CPC who received CSI had better PFS compared with those receiving less than CSI. This study supports the use of CSI in the multimodality management of patients with CPC.
对涉及脉络丛癌（CPC）的病例进行全面的文献回顾和分析，以确定最佳的放射治疗（RT）治疗野。
对 1979 年至 2008 年的英文文献进行了 PubMed 搜索，共获得 33 篇文章，其中 56 例患者提供了有关 RT 治疗野的数据。诊断时的中位年龄为 2.7 岁（范围为 1 个月至 53 岁）。54 例患者中，有 21 例（38.9%）接受了完全切除。27 例（48%）患者接受了化疗作为初始治疗的一部分。38 例（68%）患者的 RT 治疗体积为颅脊柱轴，9 例（16%）为全脑，9 例（16%）为肿瘤/肿瘤床。存活患者的中位随访时间为 40 个月。
5 年总生存率和无进展生存率（PFS）分别为 59.5%和 37.2%。完全切除（p=0.035）和颅脊柱照射（CSI）的使用（p=0.025）被发现对 PFS 有积极影响。接受 CSI 与接受全脑和肿瘤/肿瘤床 RT 的患者的 5 年 PFS 分别为 44.2%和 15.3%。在 19 例复发患者中，9 例（47%）在 RT 野内复发，6 例（32%）在 RT 野外复发，4 例（21%）在放射野内和外复发。
接受 CSI 的 CPC 患者的 PFS 优于未接受 CSI 的患者。本研究支持在 CPC 患者的多模态治疗中使用 CSI。
